BIA 31
Alternative Names: BIA-31Latest Information Update: 04 Jul 2023
Price :
$50 *
At a glance
- Originator BIAL
- Class Antiparkinsonians
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 04 Jul 2023 Discontinued - Preclinical for Parkinson's disease in Portugal (unspecified route) (BIAL pipeline, July 2023)
- 21 Jun 2022 BIA 31 is available for licensing as of 21 Jun 2022. https://www.bial.com/
- 21 Jun 2022 Preclinical trials in Parkinson's disease in Portugal (unspecified route) (BIAL pipeline, June 2022)